Advertisement


Robert J. Motzer, MD, on RCC: Quality of Life for Patients Treated With Lenvatinib-Based Therapy vs Sunitinib

2021 ASCO Annual Meeting

Advertisement

Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, discusses health-related quality-of-life data from the phase III CLEAR trial, which compared lenvatinib plus pembrolizumab or everolimus vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma (Abstract 4502).



Related Videos

Breast Cancer
Immunotherapy

Sibylle Loibl, MD, PhD, on Triple-Negative Breast Cancer: Improving Long-Term Outcomes With Durvalumab

Sibylle Loibl, MD, PhD, of the German Breast Group, discusses results from the phase III GeparNUEVO study, which investigated neoadjuvant durvalumab in addition to anthracycline/taxane-based neoadjuvant chemotherapy in patients with early triple-negative breast cancer (Abstract 506).

Colorectal Cancer
Immunotherapy

Thierry André, MD, on Pembrolizumab vs Chemotherapy in MSI-High Colorectal Cancer

Thierry André, MD, of Hôpital Saint-Antoine, discusses final overall survival data for the phase III KEYNOTE-177 study, which confirmed pembrolizumab as a new standard of care for first-line treatment of patients with microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer (Abstract 3500).

Kidney Cancer
Immunotherapy

Brian I. Rini, MD, on RCC: Pembrolizumab Plus Axitinib vs Sunitinib as First-Line Therapy

Brian I. Rini, MD, of Vanderbilt University, discusses findings from KEYNOTE-426, the longest follow-up of a checkpoint inhibitor (pembrolizumab) combined with a VEGF/VEGFR inhibitor (axitinib) for first-line clear cell renal cell carcinoma. The trial results continue to support this combination as a standard of care for patients with previously untreated disease (Abstract 4500).

Prostate Cancer

Karim Fizazi, MD, PhD, on Prostate Cancer: Abiraterone Acetate, Prednisone, and Radiotherapy in Metastatic Disease

Karim Fizazi, MD, PhD, of Institut Gustave Roussy, discusses first results from the phase III PEACE1 trial, which showed that abiraterone plus androgen-deprivation therapy and docetaxel improves radiographic progression-free survival in men with de novo metastatic prostate cancer (Abstract 5000).

Lymphoma

Ann S. LaCasce, MD, on Hodgkin Lymphoma: PET-Adapted Therapy for Bulky Disease

Ann S. LaCasce, MD, of Dana-Farber Cancer Institute, discusses results from the CALGB 50801 Alliance study, which showed that a PET scan–adapted approach may reduce the need for radiation treatment and may improve progression-free outcomes in patients with stage I/II bulky classic Hodgkin lymphoma (Abstract 7507).

Advertisement

Advertisement



Advertisement